Onconetix Business Summary

Onconetix, Inc. (ONCO) is a commercial-stage life sciences company that generates revenue through the sale of therapeutics, diagnostic licensing, and intellectual property royalties. Its primary business segments include Men’s Health, anchored by the FDA-approved BPH treatment Entadfi, and Oncology Diagnostics, centered on the Proclarix blood test licensed to Labcorp for U.S. distribution. As of February 2026, the company is executing a radical strategic pivot following its February 12 announcement to acquire Realbotix LLC, an AI-powered humanoid robotics firm, in an all-stock transaction that will shift its core focus toward autonomous healthcare and service robotics. In the biotechnology market, Onconetix operates as a nano-cap player competing against larger entities like Merck & Co. and specialized peers such as Nanoviricides and Anavex Life Sciences, currently positioning itself as a high-risk, transformative bridge between clinical oncology and generative AI robotics. Originally founded by healthcare entrepreneur Joseph Hernandez, the company is currently led by Interim CEO and CFO Karina M. Fedasz, a Columbia Business School alumna with extensive capital markets experience at Evofem Biosciences and IDW Media Holdings. The broader leadership team includes Andrew Skibo as Global Head of Biologics Operations and Brian Price as Head of Technology Strategy. Following the anticipated close of the Realbotix acquisition in late 2026, Andrew Kiguel is slated to assume the CEO role. The Board of Directors is chaired by Andrew Oakley, former CFO of Autolus Therapeutics, and includes notable industry veterans such as Dr. Thomas Meier and Dr. Ajit Singh, a partner at Artiman Ventures and Adjunct Professor at Stanford University, providing the firm with significant pedigree in both clinical execution and venture-backed technology scaling.